Distribution of single and combined prothrombotic risk factors in neonatal patients at RVT onset, in recurrent thrombosis, and in healthy controls
Prothrombotic risk factor . | Onset of renal venous thrombosis, no./sample size (%); n = 59 . | Recurrent thrombosis in carriers, no./sample size (%); n = 4 . | Control group, no./sample size (%) . |
|---|---|---|---|
| Factor V 1691G>A, total | 22/59 (37.3) | 2/22 (9.1) | 7/118 (5.9) |
| Homozygous A1691A | 1 | 1 | 0 |
| Single heterozygous 1691G>A | 13 | 0 | 7 |
| With lipoprotein(a) greater than 0.30 g/L | 5 | 1 | 0 |
| With factor II | 2 | 0 | 0 |
| With protein C deficiency | 1 | 0 | 0 |
| Factor II 20210G>A, total | 5/59 (8.5) | 0/5 (0) | 2/118 (1.7) |
| Single | 0 | 0 | 2 |
| With factor V 1691G>A | 2§ | 0 | 0 |
| With lipoprotein(a) greater than 0.30 g/L | 3 | 0 | 0 |
| Lipoprotein(a) more than 0.3 g/L, total | 17/59 (28.8) | 1/17 (5.9) | 5/118 (4.2) |
| Single | 6 | 1 | 5 |
| With factor V 1691G>A | 5§ | (1)§ | 0 |
| With factor II | 3§ | 0 | 0 |
| With Hcy greater than 10 μM* | 1 | 0 | 0 |
| Protein C deficiency, total† | 3/59 (5.0) | 1/3 (33.3) | 0 |
| Single | 2 | 1 | 0 |
| With factor V 1691G>A | 1§ | 0 | 0 |
| Antithrombin deficiency, total‡ | 3/59 (5.0) | 0 | 0 |
| Single | 3 | 0 | 0 |
| ACAs greater than 2 SDs, total | 3/59 (5.0) | 0 | 0 |
| Single | 3 | 0 | 0 |
Prothrombotic risk factor . | Onset of renal venous thrombosis, no./sample size (%); n = 59 . | Recurrent thrombosis in carriers, no./sample size (%); n = 4 . | Control group, no./sample size (%) . |
|---|---|---|---|
| Factor V 1691G>A, total | 22/59 (37.3) | 2/22 (9.1) | 7/118 (5.9) |
| Homozygous A1691A | 1 | 1 | 0 |
| Single heterozygous 1691G>A | 13 | 0 | 7 |
| With lipoprotein(a) greater than 0.30 g/L | 5 | 1 | 0 |
| With factor II | 2 | 0 | 0 |
| With protein C deficiency | 1 | 0 | 0 |
| Factor II 20210G>A, total | 5/59 (8.5) | 0/5 (0) | 2/118 (1.7) |
| Single | 0 | 0 | 2 |
| With factor V 1691G>A | 2§ | 0 | 0 |
| With lipoprotein(a) greater than 0.30 g/L | 3 | 0 | 0 |
| Lipoprotein(a) more than 0.3 g/L, total | 17/59 (28.8) | 1/17 (5.9) | 5/118 (4.2) |
| Single | 6 | 1 | 5 |
| With factor V 1691G>A | 5§ | (1)§ | 0 |
| With factor II | 3§ | 0 | 0 |
| With Hcy greater than 10 μM* | 1 | 0 | 0 |
| Protein C deficiency, total† | 3/59 (5.0) | 1/3 (33.3) | 0 |
| Single | 2 | 1 | 0 |
| With factor V 1691G>A | 1§ | 0 | 0 |
| Antithrombin deficiency, total‡ | 3/59 (5.0) | 0 | 0 |
| Single | 3 | 0 | 0 |
| ACAs greater than 2 SDs, total | 3/59 (5.0) | 0 | 0 |
| Single | 3 | 0 | 0 |
Breakdown for prothrombotic risk factors was as follows: single, n = 28; combined, n = 12.
19 μM Hcy (6 to 12 months after acute onset; confirmed in at least one family member; methylenetetrahydrofolate reductase [MTHFR] 677C>T).
5%, 7%, and 12%.
5%, 12%, and 20%.
This entry refers to the same data as an earlier table entry.